Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Candonilimab and ATRA

Phase 2Small molecule

SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cancer RecurrenceActive, not recruiting

Cancer RecurrencePhase 2

Active, not recruiting

Timeline

Expected Milestones

Q4 2026

Phase 2Active, not recruiting

Cancer Recurrence

NCT06728631

Clinical

Trials by Indication[1]

Cancer Recurrence1 trial

Candonilimab and ATRA Acid for Prevention of Oral Cancer Recurrence in Patients With OPL

Active, not recruiting·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT06728631·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Candonilimab and ATRA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Candonilimab and ATRA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Candonilimab and ATRA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Related News